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During the last 30 years the incidence of fungal infections has increased dramatically.
While the antifungal therapeutic options available are somewhat reduced, most
pathogenic microorganisms have an incredible capacity to mutate and acquire
resistance. In addition, multiple drugs are often required concomitantly to manage
clinically complex disorders. The combination of antibiotics or other compounds
with antifungal drugs, simultaneously or sequentially, is commonly adopted in clinical
practice, although without a full knowledge of the consequences. Thus, the role of
combined therapy and the effect of antibiotics upon fungal growth promotion need to be
critically evaluated and understood in order to avoid undesirable drug interactions. With
this review we intend discuss the studies that report about antibiotics inhibiting fungal
growth, as well as studies describing the synergistic effect of the combined therapy, i.e.,
associations between antibiotics or other compounds with antifungal drugs. Alternative
therapeutic protocols for fungal disease could be designed, taking advantage of such
drug combinations. Critical revision of previously published data is crucial in order to
define future research strategies.
Keywords: fungal infections, antibiotic therapy, antifungal therapy, combined therapy, synergistic effects
Introduction
An increasing number of pathogenic microorganisms develop resistance to antimicrobial agents
commonly used in medical therapy. Antibiotics are the most frequently prescribed antimicrobial
drugs. These compounds reduce human and animalmorbidity andmortality, providing the current
basis for infectious disease control. However, soon after the introduction of penicillin (1943),
reports about bacterial resistance started. The three most relevant causes of resistance are, (i) lack
of the drug target, (ii) activity of chromosomally encoded antibiotic inactivating enzymes, and (iii)
diminished uptake of the antimicrobial due to impermeability or eﬄux pumps.
On the other hand, the incidence of fungal infections during the last 30 years has increased
dramatically; however, the number of antifungal compounds remains somewhat restricted. Several
reasons were appointed to justify this increase such as the growing number of individuals
with impairment of immune status, the increase of gastro-intestinal surgery and other invasive
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procedures, the growing number of patients admitted to intensive
care units (ICUs), and the widespread use of wide spectrum
antibacterial therapy.
It is essential to stress that systemic Candida infections
are an important cause of morbidity and mortality among
patients submitted to prolonged antibiotic therapy. The rate
of bloodstream infection by Candida sp. in hospital patients
increased about 500% along the 1980s, and 6–11% of all the
positive nosocomial bloodstream infections could be attributed to
Candida sp. (Pfaller and Diekema, 2007). C. albicans, like several
other Candida species can inhabit humans as either commensal
or opportunistic pathogens, being able to cause from superﬁcial
to life threatening infections. Treatment of fungal infections
during the last 50 years has mostly been based upon fungicidal
drugs such as amphotericin B, that binds to the major fungal
sterol, ergosterol. Interestingly, the majority of clinical cases of
antifungal resistance reported involved the azole class. A more
recent group of drugs, the echinocandins, were described as
fungicidal to yeast by inhibiting the cell wall synthesis. However,
natural and acquired resistance was soon described (Walker et al.,
2010).
It is important to highlight the fact that patients at risk for
invasive fungal infections are also at risk for the development
of serious bacterial infections; therefore, both antibacterial and
other compounds may be used for prophylactic and therapeutic
purposes in parallel or in sequence with antifungal drugs
(Stergiopoulou et al., 2009).
In order to understand the eﬀect of antibacterial and other
compounds on fungal growth and on antifungal response, we
conducted a review on this topic. This review was organized
accordingly the following critical topics:
(1) Eﬀect of antibacterial compounds:
(a) Upon fungal growth
(b) In association with antifungal drugs
(2) Eﬀect of non-antibacterial drugs on antifungal therapy.
1(a) Effect of Antibacterial Compounds upon
Fungal Growth
Data from literature revealed that the risk of infection byCandida
sp. during and after antibiotic therapy was early recognized
after the use of antibiotics. An ancient work conducted by
Maclean (1962) suggested that the incidence of clinical candidosis
may increase in patients treated with tetracycline, and further
research showed that oral antibiotics administered in children,
such as tetracycline and phenoxymethyl penicillin, induced the
growth of Candida sp. It is well established that mucocutaneous
candidosis is associated with antibacterial therapy. A pilot
study demonstrated that the use of short courses of oral
antibiotics (4–6 weeks) seems to increase the prevalence of
asymptomatic vaginal Candida colonization as well as the
incidence of symptomatic vulvovaginal candidosis (Xu et al.,
2008). These results are consistent with previous studies which
demonstrated that antibiotic use seems to be a short-term
risk factor for symptomatic vulvovaginal candidosis and that
highest risk occurs during the ﬁrst month after antibiotic
use.
Candida species await any opportunity aﬀorded by
antibacterial therapy; infections by yeast organisms often follow
a course of antibiotic therapy. It is noteworthy that Candida sp.
can show overgrowth following exposure to the majority of the
antibiotics mostly by indirect eﬀects that is decrease microbial
competition. However, quinolones and aminoglycosides do not
induce candidosis as promptly or as often as cephalosporins
(Samonis et al., 1994). Cephalosporins are not active against
all bacterial isolates. In consequence, microorganisms that
are not inhibited by cephalosporin show overgrowth with
varying potential to cause infection. Cephalosporins are
prescribed for an extensive variety of infections, exhibiting
broad spectrum activity, what encourages rapid overgrowth of
some microorganisms that are neither eliminated nor inhibited.
Overgrowth is not exclusively a bacterial domain. Among the
panoply of such microorganisms, some are recognizable as
pathogens; however, others that at the beginning may behave as
commensal or seem to be of low risk status, have subsequently
been shown to cause disease.
Mulligan et al. (1982) revealed that cefoperazone induced
severe changes in fecal ﬂora, such as suppression of
Enterobacteriaceae, and increase in counts of Candida sp.
A study involving a group of persons treated with parental
ceftriaxone also showed an overgrowth of yeasts in stools; in
patients treated with cefotaxime, Candida sp. was also recovered
from throat swabs (Devrieshospers et al., 1991).
Pecquet et al. (1987) described a situation of ﬁve healthy
adults receiving oral oﬂoxacin during 5 days (Pecquet et al.,
1987); oﬂoxacin induced selective elimination of aerobic Gram-
negative bacteria. During treatment, colonization of all the
volunteers by Candida sp. was detected. The eﬀect of amoxicillin
on the ecology of skin microbial ﬂora was also investigated;
it revealed a decrease in the number of bacterial isolates and
an increase in C. albicans. Samonis et al. (1994), revealed that
amoxillin-clavulanate induced a higher and more persistent
gastrointestinal colonization by yeasts comparatively to other
tested antibiotics (Samonis et al., 1994). The eﬀect of amoxicillin
therapy on the ecology of skin microbial ﬂora in infants was
also investigated; it revealed a decrease in the number of
bacterial isolates and increase in C. albicans recovery (Brook,
2000).
Among ICU patients infections by Candida sp. are of
very high prevalence. A study performed by Charles et al.
(2005), demonstrated that broad-spectrum antibiotic therapy was
found to promote fungal growth in patients with prior yeast
colonization (Charles et al., 2005). The authors recommended the
reduction of antibiotic therapy for prevention of fungal infections
in this particular case, since most cases of invasive candidosis
in ICU setting are supposed to be subsequent to colonization
in high-risk patients. A study involving ICU patients in Ankara
Training and Research Hospital, Turkey, showed that Candida
colonization emerged more often in patients with bacterial sepsis
and in those exposed to broad spectrum antibiotics (Ergin
et al., 2013). A study concerning fungaemia in a portuguese
university hospital, revealed that 93% of the patients had received
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antibacterial drugs and in 68% of the cases, a combination
of two or more antibacterial drugs had been administered
simultaneously (Costa-de-Oliveira et al., 2008).
Another study involving antibiotic treated and untreated
Syrian hamsters inoculated intragastrically with C. albicans
showed that antibiotic treatment decreased the total population
levels of the indigenous bacterial ﬂora and predisposed
the animals to gastrointestinal overgrowth and systemic
dissemination of C. albicans in 86% of the cases (Kennedy and
Volz, 1985a). These researchers proposed that the indigenous
microﬂora inhibited C. albicans colonization and dissemination
from the intestinal tract by two possible mechanisms: (i) decrease
of the size of Candida population in the gut and, (ii) inhibition
of the mucosal binding of Candida organisms by thick layers
of bacteria in the mucus gel covering the epithelium. This
study appears to suggest that anaerobic organisms suppress
C. albicans. Hamsters treated with penicillin showed a decrease
of the population of strictly anaerobic bacteria in the cecum,
allowing an increase in facultative bacteria and promoting
C. albicans adhesion, colonization, and dissemination from the
gastrointestinal tract.
In a previous study involving mice treated with several
antibiotics administered orally, namely penicillin, clindamycin,
and vancomycin, a decrease in the total anaerobic bacterial
populations in the animals ceca was found; simultaneously
C. albicans could proliferate in the gut and subsequently
disseminate to visceral organs (Kennedy and Volz, 1985b). In
addition, it was hypothesized that presence of bacterial amines
produced by anaerobes in vagina ﬂora, as in healthy gut, may
explain why candidosis is rarely observed in concomintance
with bacterial vaginosis since such amines cause the inhibition
of germ tube formation by Candida species (Rodrigues et al.,
1999).
The perceived inhibitory eﬀect of anaerobes upon yeasts,
although by unknown mechanisms, is one of the stressed topics
by authors like Stoutenbeek et al. (1984), when proposing
selective digestive decontamination (SDD) protocols as a means
of prevention of infection in patients admitted in ICUs
(Stoutenbeek et al., 1984).
In a study involving a mouse model receiving single
carbapenems (meropenem, imipenem, and ertapenem) or a
carbapenem in association with amikacin, a substantial increase
in the murine intestinal concentration of C. albicans was found
(Samonis et al., 2013). Similar ﬁndings were found in humans.
The level of gastrointestinal colonization by Candida sp. is
related to the spectrum, the dose, the route of administration,
and pharmacodynamics and pharmacokinetic properties of the
antimicrobial given.
All these studies are summarized in Table 1. Notably, few
studies were carried out, often with limited sample size were
performed.
The explanation for antibiotic enhancement of yeast growth
is mainly indirect, being related with: (i) removal of organisms
competing for nutrients; and (ii) removal of organisms that
secrete antifungal substances. However, a possible direct eﬀect of
antibiotic drugs in yeasts should be investigated.
1(b) Effect of Antibacterial Compounds in
Association with Antifungal Drugs
It is common in clinical practice the use of antibiotics
and antifungals simultaneously or sequentially. Thus, it is
important to assess the eﬀect of combination therapy on fungal
cells.
Since the 1970s and 1980s sinergistic eﬀects between
tetracycline and amphotericin B were described. Tetracycline
can change the susceptibility pattern of C. albicans and other
pathogenic fungi to amphotericin B (Oliver et al., 2008).
Tetracycline has a direct eﬀect upon the mitochondrial function;
its inhibition eliminates the diauxic shift and in consequence
impairs sterol metabolism, which results in lower ergosterol
levels. Lower sterol levels in cells grown in presence of
tetracycline, promotes amphotericin B susceptibility due to a
higher amphotericin B to ergosterol ratio at the cell surface
(Table 2).
TABLE 1 | Antibiotic drugs regimens that promote fungal growth mainly due to an indirect effect.
Class of antibiotics Fungal organisms Model of study Sample size Reference
Tetracycline Candida sp. in vivo1 unknown Maclean (1962)
Associated with phenoxymethyl penicillin Candida sp. in vivo1 unknown Maclean (1962)
Carbapenems C. albicans in vivo2 50 Samonis et al. (2013)
Associated with amikacin C. albicans in vivo2 50 Samonis et al. (2013)
Cephalosporins Candida sp. in vivo1 4 Mulligan et al. (1982)
Yeasts in vivo1 11 Devrieshospers et al. (1991)
Fluoroquinolone Candida sp. in vivo1 5 Pecquet et al. (1987)
Penicillins C. albicans in vivo1 25 Brook (2000)
Candida spp. in vivo3 unknown Kennedy and Volz (1985b)
Associated with clavulanate Yeasts in vivo1 4 Samonis et al. (1994)
Glycopeptides Candida sp. in vivo3 unknown Kennedy and Volz (1985b)
Aminoglycosides Candida sp. in vivo3 unknown Kennedy and Volz (1985b)
Broad-spectrum antibiotic therapy Candida sp. in vivo1 593 Charles et al. (2005)
Candida sp. in vivo1 100 Ergin et al. (2013)
1Human; 2Mouse model; 3Syrian hamster model.
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TABLE 2 | Sinergistic effect between antibiotic and antifungal drugs.
Antifungals Antibiotics Fungal organisms Reference Mechanism of synergism
AMB Tetracycline Candida albicans, Aspergillus fumigatus
and Cryptococcus neoformans
Oliver et al. (2008) Inhibition of the mitochondrial function impairs sterol
metabolism, resulting in lowe ergosterol levels.
Azithromycin Fusarium sp. Clancy and Nguyen (1998) Fungal cell membrane damaged by amphotericin B, may
allow entrance of antibiotic, inhibiting protein synthesis.Rifampicin C. albicans Ansehn et al. (1976)
Del Pozo et al. (2011)
C. neoformans and Prototheca sp. Srimuang et al. (2000)
C. parapsilosis, C. krusei and
C. glabrata
El-Azizi (2007)
Doxycycline C. parapsilosis, C. krusei, and
C. glabrata
El-Azizi (2007)
Clarithromycin Candida sp. Del Pozo et al. (2011)
Quinolone Candida sp. and C. neoformans Nakajima et al. (1995)
FLU Doxycycline C. albicans Gao et al. (2013) Inhibition of protein synthesis may interfere with sterol
pathway, resulting in lower ergosterol levels.Candida sp. Miceli et al. (2009)
Tetracycline fluconazole-resistant C. albicans Shi et al. (2010)
Quinolone fluconazole-resistant C. albicans Sugar et al. (1997)
Tigecycline C. albicans biofilms Ku et al. (2010)
AMB, Amphotericin B; FLU, Fluconazole.
Clancy and Nguyen (1998), investigated the combination of
amphotericin B and azithromycin, against 26 clinical isolates of
Fusarium, and observed a synergistic eﬀect (Clancy and Nguyen,
1998). The combination of amphotericin B and azithromycin
improved the antifungal eﬀect reducing amphotericin B minimal
inhibitory concentrations (MICs) from 1 to 0.37 mg/L, while
single azithromycin exhibited no antifungal activity. Considering
the resistance of Fusarium to conventional antifungal therapy,
the combination of these two compounds could represent an
important alternative strategy in fusariosis therapy (Clancy
and Nguyen, 1998). Azithromycin acts by inhibiting protein
synthesis. An advantage related to the use of azithromycin might
arise from the excellent tissue levels that can be achieved. While
the mechanism of synergism between these two compounds
remains unclear, it has been postulated that amphotericin B, by
damaging the fungal cell membrane, may facilitate the entrance
of azithromycin into the cells; once inside the cells azithromycin
might act by inhibiting fungal protein synthesis.
Data already published in 1976, demonstrated that
amphotericin B combined with rifampicin impaired growth
of C. albicans, and a pronounced fungistatic eﬀect was obtained
with therapeutically attainable concentrations of both these
drugs (Ansehn et al., 1976). Moreover, it was demonstrated that
rifampicin alone impaired the growth of this species.
Srimuang et al. (2000), evaluated the eﬀect of amphotericin
B alone and combined with rifampicin against 71 isolates of
Cryptococcus neoformans, demonstrating that this combination
resulted in synergistic eﬀect.
It has been demonstrated that non-albicans Candida species
(NAC), considered both colonizers, and pathogens, can cause
serious nosocomial bloodstream infections. Moreover, 35–65%
of all the candidemias were such species (Krcmery and Barnes,
2002), and there is a tendency to its increase. El-Azizi (2007),
demonstrated that treatment with amphotericin B associated
with rifampicin or doxycycline enhanced the killing activity of the
antifungal agent in bioﬁlms ofCandida parapsilosis,C. krusei, and
C. glabrata (El-Azizi, 2007). Antifungal activity of amphotericin
B increased about 30–35% in presence of doxycycline; a
synergistic eﬀect was observed with concentrations of 512 mg/L
of doxycycline. It is noteworthy that the tested antibiotics alone
did not exhibit antifungal activity. The synergistic eﬀect of the
antibiotics could be related to the fact that amphotericin B
binds to the sterols in the fungal cell membrane, thus increasing
the antibacterial permeability; rifampicin interferes with RNA
synthesis, while doxycycline interferes with protein synthesis.
A recent study has also described synergistic eﬀects between
amphotericin B and clarithromycin, and between amphotericin
B and rifampicin against Candida bioﬁlms. Attending to such
results, the association between the antibacterial agents tested
could represent a very interesting therapeutical approach for the
treatment of Candida bioﬁlm-related infections (Del Pozo et al.,
2011).
Gao et al. (2013) explored the antifungal activity of
ﬂuconazole in combination with doxycycline against C. albicans.
The results revealed a strong synergism against planktonic
cells of ﬂuconazole-resistant isolates. The same author’s also
demonstrated a weaker antifungal eﬀect of ﬂuconazole combined
with doxycycline against C. albicans bioﬁlms compared with
planktonic cells, being this eﬀect time dependent. Miceli et al.
(2009) also showed that doxycycline combined with ﬂuconazole
increased the killing activity of the antifungal upon bioﬁlms
by Candida sp. In this report, single doxycycline (2048 and
1024 mg/L) resulted in to 85% reduction of the metabolic
activity of C. albicans bioﬁlm; single ﬂuconazole exhibited a
lower activity (22.9 % reduction); interestingly, the combination
of both compounds resulted in an additive eﬀect. Such results
suggest that high-dose doxycycline in combination with standard
antifungal agentsmight play an important role in the treatment of
Candida biomaterial-related, like is the case of medical indwelling
device infections.
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A recent study showed that ﬂuconazole acts synergistically
with minocycline against ﬂuconazole-resistant C. albicans,
resulting in a signiﬁcant decrease of the MIC value when both
compounds are combined comparatively to single ﬂuconazole
(Shi et al., 2010). This combination could represent a valid option
to overcome ﬂuconazole resistance. The minimum inhibitory
concentrations for 80% of inhibition (MIC80) of ﬂuconazole and
minocycline were 512 and 256 mg/L, respectively. The results
revealed that a concentration of 4 mg/L of minocycline (which
corresponds to a concentration easily achieved in human serum
and other body ﬂuids with conventional therapeutic dosages),
in combination with ﬂuconazole resulted in a ﬂuconazole MIC
decrease to 8 mg/L. Data from the literature clearly demonstrate
that it is very diﬃcult for ﬂuconazole to penetrate C. albicans
bioﬁlms when used alone. However, with the association of
minocycline the amount of ﬂuconazole penetrating C. albicans
bioﬁm increases signiﬁcantly (Shi et al., 2010). The same
study also showed that the association of minocycline with
ﬂuconazole could signiﬁcantly reduce cell growth and cell
activity. At a concentration of minocycline of 16-32 mg/L,
the MIC of ﬂuconazole decreased to 1–2 mg/L. In another
study, tigecycline at concentrations corresponding to 2048 mg/L
inhibited the growth of planktonic cells of C. albicans in 50%
(Ku et al., 2010). Moreover, another study reported about
an investigational quinolone that increased the activity of
amphotericin B and ﬂuconazole both in vitro an in vivo against
a variety of fungal planktonic cells (Nakajima et al., 1995).
Sugar et al. (1997) demonstrated that ﬂuconazole was eﬀective
together with trovaﬂoxacin in the treatment of mice infected
with ﬂuconazole-resistant C. albicans (Sugar et al., 1997). Such
result suggests that combination therapy may have clinical
potential.
Since the ability of microorganisms to form bioﬁlms is
often involved in severe infections, with the consequent
emergence of resistance to the host immune system response
and to antimicrobial therapy, it is important to emphasize that
antibacterial compounds alone or combined with antifungals
could also play a relevant role against fungal bioﬁlms. A study
developed by Ku et al. (2010) showed that 2048 mg/L of TIG
reduced the metabolic activity of mature bioﬁlms in 84.2%; the
association of 512 mg/L of TIG with ﬂuconazole, at all the tested
concentrations, resulted in an extra reduction of the metabolic
activity of mature bioﬁlms (Ku et al., 2010).
A possible explanation for the synergistic eﬀects between
ﬂuconazole and antibiotics that act by inhibition of RNA or
protein synthesis could be related with the inhibition of protein
synthesis, which may interfere with sterol pathway ultimately,
decreasing the ergosterol levels. Details about the most relevant
studies addressing synergistic eﬀects between antibiotic and
antifungal drugs are detailed in Table 2.
2. Effect of Non-Antibacterial Drugs on
Antifungal Therapy
Only synergistic eﬀects between antifungals and other chemical
compounds, other than, classic antibiotics were reviewed; details
are described in Table 3.
Chloroquine exhibits antifungal activity against fungal
pathogens. Shinde et al. (2013) revealed that chloroquine
potentiates the anti-bioﬁlm activity of ﬂuconazole and
voriconazole upon C. albicans. A study involving Saccharomyces
cerevisiae also demonstrated that chloroquine inhibits the yeast
growth by iron deprivation (Emerson et al., 2002). While similar
eﬀects could occur with C. albicans in presence of ﬂuconazole
and voriconazole, the precise mechanism remains yet to be
elucidated (Shinde et al., 2013).
Alem and Douglas (2004) showed that aspirin also exhibited
antibioﬁlm activity in vitro; in combination with antifungal
agents it could be used against bioﬁlm associated Candida
infections (Alem and Douglas, 2004). A study performed at
our laboratory revealed that a combination of ﬂuconazole
with sodium salicylate or ibuprofen induced a synergistic
activity against C. albicans, due to blockage of eﬄux pumps
(Pina-Vaz et al., 2000). Bellamy et al. (1993) demonstrated
that lactoferricin B exhibits fungicidal eﬀect upon Candida
species through direct interaction with the cell surface. Kuipers
et al. (1999) showed a synergistic activity between lactoferrin
TABLE 3 | Sinergistic effect between other non-antibacterial compounds and antifungal drugs.
Antifungals Other compounds Fungal organisms Reference Mechanism of synergism
Azoles Chloroquine C. albicans Shinde et al. (2013) Iron deprivation
S. cerevisiae Emerson et al. (2002)
Ibuprofen C. albicans Pina-Vaz et al. (2000) Efflux pump blocker; increase of azole content
Lactoferrin Candida sp. Bellamy et al. (1993) Direct interaction with the cell surface
Kuipers et al. (1999)
Sida Cordifolia compounds Candida sp. Ouédraogo et al. (2012) Immunostimulatory effect
Sertraline Candida and Cryptococcus sp. Spitzer et al. (2011) Alteration of membrane permeability
Statins Dermatophyte sp. Nyilasi et al. (2014) Not described
AMB Lactoferrin Candida sp. Bellamy et al. (1993) Direct interaction with the cell surface
Statins Dermatophyte sp. Nyilasi et al. (2014) Not described
5-FC Lactoferrin Candida sp. Bellamy et al. (1993) Direct interaction with the cell surface
Nystatin Sida Cordifolia compounds Candida sp. Ouédraogo et al. (2012) Immunostimulatory effect
AMB, Amphotericin B; 5-FC, 5-fluorocytosine.
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and amphotericin B, 5-ﬂuorocytosine and ﬂuconazole against
Candida species. However, the most successful combination was
lactoferrin and ﬂuconazole.
A recent report describes synergistic interactions between
statins and antifungals (Nyilasi et al., 2014). Authors suggest
that statins exhibit antifungal eﬀect against dermatophyte fungi,
which could constitute promising compounds for combination
therapy.
The search for plants with antifungal activity has gained
increasing importance; higher plants produce diverse secondary
metabolites with diﬀerent biological activities. These compounds
may be exhibit antimicrobial eﬀects. Ouédraogo et al. (2012)
noticed that alkaloid compounds from Sida Cordifolia L
(Malvaceae) in combination with nystatin and clotrimazole
exhibited inhibitory eﬀects against Candida strains. A hypothesis
for this eﬀect can be related with alteration of membrane
permeability.
The combination of ﬂuconazole with sertraline, an
antidepressant, was eﬀective against Candida and Cryptococcus
strains, including drug-resistant clinical isolates of Candida, in
an in vivo model (Spitzer et al., 2011). Such result may be related
with concomitant immunostimulatory eﬀect.
Conclusion
While the interaction between diﬀerent antimicrobials and
with other compounds still remains unclariﬁed in certain
domains, there is certainly place for additional and more
comprehensive studies addressing additive and synergistic eﬀects
between antibacterials and antifungals, in particular, including
preliminary clinical trials. The rationale for such studies arises
from the clinical relevance that fungal pathogens have assumed
during the recent past years, the economic and social burden
that fungal infections represent for public health systems and
the inherent therapeutic challenges, namely in terms of safety
and high eﬃcacy antifungal regimens. Additional studies, in
particular addressing the topic of combination therapy, are
highly needed to provide sound scientiﬁc support for the
clinical association of classic antifungals and non-conventional
antifungals drugs. Research in this ﬁeld may ultimately provide
valuable solutions for such demanding societal challenges.
Regarding future research we now come forward with several
suggestions that would help to elucidate questions related to
the controversial topics discussed in this review. First, it is
crucial to understand whether the stimulus for fungal growth
is related to the inhibition of competition between fungi and
bacteria or if the antibacterial compounds could act directly upon
fungal cells. Simultaneously, it is crucial to pursue experiments
in order to study the eﬀect between major antifungal classes –
azoles, echinocandins and polyenes – and antibiotics that act
impair RNA/protein synthesis and target the cell membrane,
since data from literature suggested that these are the most
promising combinations. This kind of studies should be involve
to a signiﬁcant wide range of species and isolates, since in most
of the studies described above, samples sizes were invariably
reduced. Ultimately, such results would support the design of
novel therapeutic guidelines for antimicrobial use (alone and in
association), aiming to prevent or treat invasive fungal infections.
This issue is particularly important to ensure therapeutic success
and to limit the emergence of antifungal resistance.
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